{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foperations-utopia.simplecast.com%2Fepisodes%2F13-why-start-with-chaos-with-jake-doran-BOnoBPrr","width":444,"version":"1.0","type":"rich","title":"13 | Why Start With Chaos? - with Jake Doran","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/df950f79-0fa8-4033-ad58-536486f0ec84/b26b99de-b0dc-4c95-b860-ed0ef11d180c/image_7.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/560680ed-c008-4464-937d-1e11cb55bdf7\" height=\"200\" width=\"100%\" title=\"13 | Why Start With Chaos? - with Jake Doran\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Matt sits down with longtime industry colleague Jake Doran to pick at one of regulatory operations' oldest wounds. Every new biotech builds its information management from scratch, usually badly, and pays to clean it up later. Jake has lived this from both ends, running technology at J&J and Bausch Health and then leading digital at Lykos Therapeutics as it moved from clinical startup toward commercial.\n\nJake opens with a contrarian take: small, early-stage companies may actually have the edge over 100-year-old legacy pharma in the AI era. Their systems are cleaner, their data sets are smaller, and they can build \"AI forward\" from day one. Meanwhile the big players roll out Copilot to tens of thousands of people and bolt AI onto processes nobody has touched in years.\n\nMatt pushes back. If small companies have the edge, why does the industry let them start from chaos at all? The conversation runs through budget realities, what to clean up first, AI-assisted TMF migration, why standards take a decade, functional fiefdoms, patient data privacy, and why AI has to be defensible and traceable rather than just clever."}